106 related articles for article (PubMed ID: 1313740)
1. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse.
Treskes M; Boven E; Holwerda U; Pinedo HM; van der Vijgh WJ
Cancer Res; 1992 Apr; 52(8):2257-60. PubMed ID: 1313740
[TBL] [Abstract][Full Text] [Related]
2. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
3. Selective reduction of cis-diamminedichloroplatinum(II) nephrotoxicity by ebselen.
Baldew GS; McVie JG; van der Valk MA; Los G; de Goeij JJ; Vermeulen NP
Cancer Res; 1990 Nov; 50(21):7031-6. PubMed ID: 2208170
[TBL] [Abstract][Full Text] [Related]
4. Cytostatic activity of cisplatin in the presence of WR2721 and its thiol metabolite WR1065 in OVCAR-3 human ovarian cancer cells as compared to V79 fibroblasts.
Treskes M; Nijtmans L; Fichtinger-Schepman AM; van der Vijgh WJ
Anticancer Res; 1992; 12(6B):2261-5. PubMed ID: 1338281
[TBL] [Abstract][Full Text] [Related]
5. Selenium-induced protection against cis-diamminedichloroplatinum(II) nephrotoxicity in mice and rats.
Baldew GS; van den Hamer CJ; Los G; Vermeulen NP; de Goeij JJ; McVie JG
Cancer Res; 1989 Jun; 49(11):3020-3. PubMed ID: 2720662
[TBL] [Abstract][Full Text] [Related]
6. Protection against late effects of radiation by S-2-(3-aminopropylamino)-ethylphosphorothioic acid.
Grdina DJ; Carnes BA; Grahn D; Sigdestad CP
Cancer Res; 1991 Aug; 51(16):4125-30. PubMed ID: 1651155
[TBL] [Abstract][Full Text] [Related]
7. Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice.
Treskes M; Boven E; van de Loosdrecht AA; Wijffels JF; Cloos J; Peters GJ; Pinedo HM; van der Vijgh WJ
Eur J Cancer; 1994; 30A(2):183-7. PubMed ID: 8155393
[TBL] [Abstract][Full Text] [Related]
8. Time dependent protection of amifostine from renal and hematopoietic cisplatin induced toxicity.
Asna N; Lewy H; Ashkenazi IE; Deutsch V; Peretz H; Inbar M; Ron IG
Life Sci; 2005 Mar; 76(16):1825-34. PubMed ID: 15698860
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum(II) by WR-2721 without altering its antitumor properties.
Yuhas JM; Culo F
Cancer Treat Rep; 1980 Jan; 64(1):57-64. PubMed ID: 6247064
[TBL] [Abstract][Full Text] [Related]
10. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
[TBL] [Abstract][Full Text] [Related]
11. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts.
Staffhorst RW; van der Born K; Erkelens CA; Hamelers IH; Peters GJ; Boven E; de Kroon AI
Anticancer Drugs; 2008 Aug; 19(7):721-7. PubMed ID: 18594214
[TBL] [Abstract][Full Text] [Related]
13. Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors.
Dominguez MF; Macias RI; Izco-Basurko I; de La Fuente A; Pascual MJ; Criado JM; Monte MJ; Yajeya J; Marin JJ
J Pharmacol Exp Ther; 2001 Jun; 297(3):1106-12. PubMed ID: 11356935
[TBL] [Abstract][Full Text] [Related]
14. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate.
Bodenner DL; Dedon PC; Keng PC; Katz JC; Borch RF
Cancer Res; 1986 Jun; 46(6):2751-5. PubMed ID: 3009000
[TBL] [Abstract][Full Text] [Related]
15. Amifostine increases cure rate of cisplatin on ascites hepatoma 22 via selectively protecting renal thioredoxin reductase.
Zhang J; Wang X; Lu H
Cancer Lett; 2008 Feb; 260(1-2):127-36. PubMed ID: 18039557
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity, induction of cross-resistance, and nephrotoxicity of a new platinum analogue, cis-1,1-diaminomethylcyclohexaneplatinum(II) sulfate, and of cis-diamminedichloroplatinum(II) in an immunocytoma model in the LOU/M rat.
de Jong WH; Steerenberg PA; Vos JG; Bulten EJ; Verbeek F; Kruizinga W; Ruitenberg EJ
Cancer Res; 1983 Oct; 43(10):4927-34. PubMed ID: 6683993
[TBL] [Abstract][Full Text] [Related]
17. Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate.
Treskes M; Nijtmans LG; Fichtinger-Schepman AM; van der Vijgh WJ
Biochem Pharmacol; 1992 Mar; 43(5):1013-9. PubMed ID: 1313234
[TBL] [Abstract][Full Text] [Related]
18. Antitumour activity of cis-diamminedichloroplatinum (II) against human tumour xenografts depends on its area under the curve in nude mice.
Kurihara N; Kubota T; Hoshiya Y; Otani Y; Watanabe M; Kumai K; Kitajima M
J Surg Oncol; 1996 Feb; 61(2):138-42. PubMed ID: 8606546
[TBL] [Abstract][Full Text] [Related]
19. Tyrphostin 4-nitrobenzylidene malononitrile reduces chemotherapy toxicity without impairing efficacy.
Novogrodsky A; Weisspapir M; Patya M; Meshorer A; Vanichkin A
Cancer Res; 1998 Jun; 58(11):2397-403. PubMed ID: 9622080
[TBL] [Abstract][Full Text] [Related]
20. WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.
Treskes M; van der Vijgh WJ
Cancer Chemother Pharmacol; 1993; 33(2):93-106. PubMed ID: 8261581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]